A Long-term, Continued Treatment and Follow-up Study in Subjects with Hematologic Malignancies Treated with Duvelisib (IPI-145)
Treatment Location: N/A
Primary Objectives: To capture long-term safety data in subjects with hematologic malignancies treated with duvelisib. Secondary Objectives: The long-term clinical activity of duvelisib in subjects with hematologic malignancies. OS of subjects with hematologic malignancies treated with duvelisib.
IRB Review and Approval Date: 10/28/2016
Recruitment Status: Closed
Projected Accrual: N/A
Information and next steps
For general questions about clinical trials: